Neuronetics Common Stock Total Equity from 2010 to 2024

STIM Stock  USD 1.08  0.11  9.24%   
Neuronetics Common Stock Total Equity yearly trend continues to be very stable with very little volatility. Common Stock Total Equity is likely to grow to about 329.6 K this year. Common Stock Total Equity is the total value of common stock equity held by shareholders, representing their ownership interest in the company. View All Fundamentals
 
Common Stock Total Equity  
First Reported
2017-12-31
Previous Quarter
285 K
Current Value
288 K
Quarterly Volatility
80.3 K
 
Covid
Check Neuronetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neuronetics' main balance sheet or income statement drivers, such as Interest Income of 3.3 M, Depreciation And Amortization of 1.4 M or Interest Expense of 4.2 M, as well as many indicators such as Price To Sales Ratio of 1.49, Dividend Yield of 0.0 or PTB Ratio of 1.94. Neuronetics financial statements analysis is a perfect complement when working with Neuronetics Valuation or Volatility modules.
  
Check out the analysis of Neuronetics Correlation against competitors.
To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.

Latest Neuronetics' Common Stock Total Equity Growth Pattern

Below is the plot of the Common Stock Total Equity of Neuronetics over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. Neuronetics' Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neuronetics' overall financial position and show how it may be relating to other accounts over time.
Common Stock Total Equity10 Years Trend
Slightly volatile
   Common Stock Total Equity   
       Timeline  

Neuronetics Common Stock Total Equity Regression Statistics

Arithmetic Mean117,307
Geometric Mean18,747
Coefficient Of Variation114.44
Mean Deviation122,994
Median2,000
Standard Deviation134,248
Sample Variance18B
Range327.6K
R-Value0.92
Mean Square Error3.1B
R-Squared0.84
Slope27,551
Total Sum of Squares252.3B

Neuronetics Common Stock Total Equity History

2024329.6 K
2023313.9 K
2021273 K
2020191 K
2019186 K
2018177 K

About Neuronetics Financial Statements

Neuronetics investors utilize fundamental indicators, such as Common Stock Total Equity, to predict how Neuronetics Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Common Stock Total Equity313.9 K329.6 K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Neuronetics is a strong investment it is important to analyze Neuronetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neuronetics' future performance. For an informed investment choice regarding Neuronetics Stock, refer to the following important reports:
Check out the analysis of Neuronetics Correlation against competitors.
To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.
You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuronetics. If investors know Neuronetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuronetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.10)
Revenue Per Share
2.453
Quarterly Revenue Growth
(0.07)
Return On Assets
(0.17)
Return On Equity
(1.00)
The market value of Neuronetics is measured differently than its book value, which is the value of Neuronetics that is recorded on the company's balance sheet. Investors also form their own opinion of Neuronetics' value that differs from its market value or its book value, called intrinsic value, which is Neuronetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuronetics' market value can be influenced by many factors that don't directly affect Neuronetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuronetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuronetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuronetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.